The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep apnea (OSA). The present study is a Phase 3 open label continuation protocol enrolling qualifying participants who completed one of the parent Phase 3 double-blind placebo-controlled studies, APC-APN-304 or APC-APN-305.

开始日期2024-07-03

申办/合作机构

Apnimed, Inc.

NCT06400615

/ Completed临床2期

Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide, Semaglutide or Liraglutide

开始日期2024-05-20

申办/合作机构

Apnimed, Inc.

NCT05813275

/ Completed临床3期

Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (SynAIRgy Study)

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.

开始日期2023-09-16

申办/合作机构

Apnimed, Inc.

100 项与 Aroxybutynin/Atomoxetine 相关的临床结果

登录后查看更多信息

100 项与 Aroxybutynin/Atomoxetine 相关的转化医学

登录后查看更多信息

100 项与 Aroxybutynin/Atomoxetine 相关的专利（医药）

登录后查看更多信息

项与 Aroxybutynin/Atomoxetine 相关的文献（医药）

2025-10-01·Contemporary Clinical Trials Communications

Aroxybutynin and atomoxetine (AD109) for the treatment of obstructive sleep apnea: Rationale, design and baseline characteristics of the phase 3 clinical trials

Article

作者: Strollo, Patrick J ; Werner, Andrea ; Taranto-Montemurro, Luigi ; Farkas, Ron ; Cronin, John ; Patel, Sanjay R ; Pho, Huy ; Yee, John

Introduction:

Two key factors leading to obstructive sleep apnea (OSA) pathogenesis include relaxation of upper airway muscles at sleep onset and their insufficient reactivation during obstructive events. Medications that address this neuromuscular dysfunction by increasing upper airway tone during sleep represent a potential strategy for mitigating OSA.

Methods:

AD109 is an investigational, once-daily oral agent taken at bedtime that combines an antimuscarinic, aroxybutynin (2.5 mg), with a selective norepinephrine reuptake inhibitor, atomoxetine (75 mg). LunAIRo (NCT05811247) and SynAIRgy (NCT05813275) are two ongoing, placebo-controlled 51-week and 26-week phase 3 clinical trials, respectively, investigating the efficacy and safety of AD109 to treat mild to severe OSA. Participants include adults with an apnea-hypopnea index with 4% desaturation (AHI₄) >5 who either refuse or fail to tolerate positive airway pressure. Participants (LunAIRo: N = 660; SynAIRgy: N = 646) were randomized 1:1 to receive AD109 or placebo. We hypothesize that AD109 will significantly reduce AHI₄ and symptomatic fatigue compared to placebo in people with OSA. The primary outcome for both trials is the change from baseline to Week 26 in AHI₄ in the AD109 arm versus placebo. Key secondary outcomes include changes from baseline in oxygen desaturation index with 3% desaturation, hypoxic burden based on 4% desaturation, Patient Reported Outcome Measurement Information System (PROMIS)-Fatigue, and proportion of participants with ≥50% reduction in AHI₄ at Week 26.

Discussion:

LunAIRo and SynAIRgy are fully enrolled, large Phase 3 clinical trials designed to confirm and extend our understanding of the safety and efficacy of AD109, a combination oral drug targeting the underlying neuromuscular dysfunction contributing to upper airway muscle collapse during sleep in adults with OSA.

2023-12-15·American journal of respiratory and critical care medicine

The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial

Article

作者: Corser, Bruce ; Ojile, Joseph M. ; Taranto-Montemurro, Luigi ; Maynard, James ; Drake, Christopher L. ; Rosenberg, Russell ; Schweitzer, Paula K. ; Thein, Stephen G. ; Abaluck, Brian ; Sangal, R. Bart

Abstract:

Rationale:

Obstructive sleep apnea (OSA) is a common sleep disorder for which the principal treatment option, continuous positive airway pressure, is often poorly tolerated. There is currently no approved pharmacotherapy for OSA. However, recent studies have demonstrated improvement in OSA with combined antimuscarinic and noradrenergic drugs.

Objectives:

The aim of this study was to evaluate the efficacy and safety of AD109, a combination of the novel antimuscarinic agent aroxybutynin and the norepinephrine reuptake inhibitor atomoxetine, in the treatment of OSA.

Methods:

Phase II randomized, double-blind, placebo-controlled, parallel-group, 4-week trial comparing AD109 2.5/75 mg, AD109 5/75 mg, atomoxetine 75 mg alone, and placebo (www.clinicaltrials.gov identifier NCT 05071612).

Measurements and Main Results:

Of 211 randomized patients, 181 were included in the prespecified efficacy analyses. Sleep was assessed by two baseline and two treatment polysomnograms. Apnea–hypopnea index with a 4% desaturation criterion (primary outcome) was reduced from a median (IQR) of 20.5 (12.3–27.2) to 10.8 (5.6–18.5) in the AD109 2.5/75 mg arm (−47.1%), from 19.4 (13.7–26.4) to 9.5 (6.1–19.3) in the AD109 5/75 mg arm (−42.9%; both P < 0.0001 vs. placebo), and from 19.0 (11.8–28.8) to 11.8 (5.5–21.5) with atomoxetine alone (−38.8%; P < 0.01 vs. placebo). Apnea–hypopnea index with a 4% desaturation criterion decreased from 20.1 (11.9–25.9) to 16.3 (11.1–28.9) in the placebo arm. Subjectively, there was improvement in fatigue with AD109 2.5/75 mg (P < 0.05 vs. placebo and atomoxetine). Atomoxetine taken alone decreased total sleep time (P < 0.05 vs. AD109 and placebo). The most common adverse events were dry mouth, insomnia, and urinary hesitancy.

Conclusions:

AD109 showed clinically meaningful improvement in OSA, suggesting that further development of the compound is warranted.Clinical trial registered with www.clinicaltrials.gov (NCT 05071612).

2022-12-01·Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA

Article

作者: Thein, Stephen ; Abaluck, Brian ; Rosenberg, Russell

STUDY OBJECTIVE:

Obstructive sleep apnea is a common and serious sleep disorder for which treatment remains challenging due to lack of adherence to approved therapies. Previous pharmacological studies addressing sleep-related upper airway muscle hypotonia suggested that the combination of atomoxetine and oxybutynin is effective in treating obstructive sleep apnea. The current study is with aroxybutynin (AD109), a new enantiomerically pure form of oxybutynin with better safety profile compared to racemic oxybutynin.

METHODS:

This was a randomized, double-blind, placebo-controlled, crossover study in patients with mild to moderate obstructive sleep apnea. Each received low-dose AD109 (37.5/2.5 mg), high-dose AD109 (75/2.5 mg), and placebo at bedtime across 3 overnight periods in a randomized order. Adverse events were collected by telephone contact with participants during each washout period. The primary endpoint was change in hypoxic burden and secondary endpoint was apnea-hypopnea index.

RESULTS:

Patients treated with both the high and low doses of AD109 had a statistically significant and clinically meaningful difference from placebo in hypoxic burden. Median [interquartile range] hypoxic burden for participants on placebo was 13.9[4.5-21.9] (%min)/h vs 2.3[0.1-10.5] (%min)/h for patients on the high dose (P < .001) and to 7.3[2-12.5] (%min)/h on the low dose (P < .01). Apnea-hypopnea index went from a median of 13.2[8.0-19.1] events/h on placebo reduced to 5.5[2.2 to 9.6] events/h on the high dose (P < .001) and to 7.8[4-13.7] events/h on the low dose (P < .05). AD109 demonstrated a favorable safety profile.

CONCLUSIONS:

This study provides additional support that a pharmacological intervention for obstructive sleep apnea, namely the combination of atomoxetine and aroxybutynin, offers promising results. Additional development of this compound and others is warranted.

CLINICAL TRIAL REGISTRATION:

Registry: ClinicalTrials.gov; Name: AD109 Dose Finding in Mild to Moderate OSA; URL: https://clinicaltrials.gov/ct2/show/NCT04631107; Identifier: NCT04631107.

CITATION:

Rosenberg R, Abaluck B, Thein S. Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA. J Clin Sleep Med. 2022;18(12):2837-2844.

112

项与 Aroxybutynin/Atomoxetine 相关的新闻（医药）

2026-07-14

·药明康德

治疗打呼噜！FDA受理口服疗法上市申请；FDA再批准阿尔茨海默病皮下注射疗法…… | 产业新闻

治疗打呼噜！FDA受理口服疗法上市申请 Apnimed今日宣布，美国FDA已受理AD109（aroxybutynin 2.3 mg/atomoxetine 75 mg）的新药申请（NDA），用于治疗成人阻塞性睡眠呼吸暂停（OSA）。FDA已将该申请的PDUFA日期定为2027年2月28日。此次申请主要获得Apnimed的3期临床项目数据支持，其中包括在轻度、中度和重度OSA成人患者中开展的随机、双盲、安慰剂对照SynAIRgy和LunAIRo试验。在两项试验中，AD109均显著降低呼吸暂停低通气指数（AHI），并改善缺氧负荷和氧减指数等血氧相关指标。AD109在3期临床项目中总体耐受性良好，最常见不良事件为口干、失眠和恶心，与此前AD109临床试验观察结果一致。 AD109是一款在研、每日一次的睡前口服药物，旨在改善患者睡眠期间的血氧状况，并针对OSA患者上气道塌陷的神经肌肉根源发挥作用。该药是一款潜在“first-in-class”疗法，由新型抗毒蕈碱药aroxybutynin与选择性去甲肾上腺素再摄取抑制剂atomoxetine组成。AD109旨在通过便捷的口服治疗方式降低干预复杂性，帮助更多患者获得有效且具有恢复作用的睡眠。面对目前较为复杂且具有侵入性的OSA治疗选择，若AD109获批，其有望为OSA患者提供一种便利的口服治疗方案，帮助改善血氧状况和整体健康。 FDA再批准阿尔茨海默病皮下注射疗法卫材（Eisai）日前宣布，美国FDA已批准其与渤健（Biogen）联合开发的Leqembi Iqlik（lecanemab）每周一次皮下注射制剂的补充生物制品许可申请（sBLA），作为早期阿尔茨海默病（AD）治疗的起始给药方案。此次批准获得一套综合临床数据的支持。相关数据涵盖多项研究和多种给药方案。其中，3期Clarity AD研究18个月核心研究结束后开展的长期扩展（LTE）研究亚研究显示，每周一次皮下注射lecanemab可达到与静脉给药相当的药物暴露水平，支持其获得相似的临床疗效和生物标志物获益，包括清除淀粉样蛋白。与药物暴露相关的不良事件方面，皮下注射给药发生淀粉样蛋白相关影像学异常伴水肿（ARIA-E）的比例预计与静脉给药相当。总体而言，皮下注射的安全性特征与静脉给药基本相似。皮下注射Leqembi可观察到注射相关反应，其中多数为局部反应，而全身性反应较少见。 Leqembi是一款靶向聚集态可溶性和不溶性β淀粉样蛋白（Aβ）的人源化IgG1单克隆抗体。该药可优先结合并清除具有毒性的Aβ原纤维，同时靶向并减少Aβ斑块。Aβ原纤维被认为是具有较强神经毒性的Aβ聚集形式之一，可参与AD相关脑损伤和认知功能下降。 6500万美元！新锐开发变构小分子 Draig Therapeutics近日宣布完成超额认购的6500万美元B轮融资，本轮融资由Deep Track Capital领投，Janus Henderson Investors、Marshall Wace、British Business Bank和Jefferson Life Sciences等机构参与。公司表示，本轮融资所得资金将用于加速推进其临床研发管线。Draig Therapeutics正在开发具有高度特异性的AMPA和GABAA受体调节剂，旨在对神经精神疾病相关的主要神经环路实现安全、精准的调控。 Draig Therapeutics的核心项目DT-101是一款AMPA受体增强剂，即正向变构调节剂（PAM），旨在满足重度抑郁障碍（MDD）患者尚未满足的治疗需求。目前，多项评估DT-101治疗MDD患者疗效的2期临床研究正在进行中，其中包括一项评估DT-101单药治疗的全球性研究，以及一项在美国开展的DT-101辅助治疗研究。参考资料： [1] Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (OSA). Retrieved July 14, 2026 from https://www.prnewswire.com/news-releases/apnimed-announces-fda-acceptance-of-new-drug-application-for-ad109-an-investigational-oral-pill-to-treat-adults-with-obstructive-sleep-apnea-osa-302825008.html [2] FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease. Retrieved July 14, 2026 from https://www.prnewswire.com/news-releases/fda-approves-leqembi-iqlik-lecanemab-irmb-subcutaneous-injection-as-a-starting-dose-for-early-alzheimers-disease-302824479.html [3] Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders. Retrieved July 14, 2026 from https://www.businesswire.com/news/home/20260713150574/en/Draig-Therapeutics-Closes-Oversubscribed-%2465-Million-Series-B-to-Accelerate-Development-of-Highly-Specific-AMPA-and-GABAA-Receptor-Modulators-in-Neuropsychiatric-Disorders 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新……

2026-07-14

·PRNewswire

Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (OSA)

The FDA assigned a PDUFA target action date of February 28, 2027 If approved, AD109 has the potential to become the first oral pharmacologic therapy designed to address the neuromuscular root cause of upper airway collapse for the millions of people living with OSA CAMBRIDGE, Mass., July 14, 2026 /PRNewswire/ -- Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that the U.S. Food and Drug Administration ("FDA") has accepted for review the New Drug Application ("NDA") filing of AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg) for the treatment of adults with obstructive sleep apnea ("OSA"). The FDA has assigned a Prescription Drug User Fee Act ("PDUFA") target action date of February 28, 2027. "The FDA acceptance of our NDA is an important milestone for Apnimed as we advance toward our goal of expanding treatment options for people with OSA who continue to need more accessible solutions," said Kevin Lind, Chief Executive Officer of Apnimed. "The NDA is supported by a clinical data package that reflects years of scientific innovation focused on a major unmet need. We believe AD109 has the potential to offer an important new treatment option for adults with OSA, if approved, and we look forward to engaging with the FDA during its review." The NDA submission is supported by data from Apnimed's Phase 3 clinical program, including the SynAIRgy and LunAIRo randomized, double-blind, placebo-controlled trials evaluating AD109 in adults with mild, moderate, and severe OSA. Across both trials, AD109 demonstrated statistically significant reductions in apnea-hypopnea index (AHI), along with improvements in oxygenation metrics, including hypoxic burden and oxygen desaturation index. AD109 was generally well-tolerated in its Phase 3 clinical program, and the most common adverse events were dry mouth, insomnia and nausea, which were consistent with earlier AD109 clinical trials. About AD109 AD109 is investigational and is designed to be the first potential pharmacological treatment to improve oxygenation during sleep and target the neuromuscular root cause of upper airway collapse in people with OSA. It is a potentially first-in-class combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor. AD109 is a once-daily oral pill taken at bedtime that is designed to lower the complexity of intervention and may help more people benefit from effective, restorative sleep. In a disease treatment landscape characterized by complex and invasive treatment options, AD109, if approved, may offer a convenient oral solution to help improve oxygenation and health for people living with OSA. About Obstructive Sleep Apnea OSA is a serious, chronic sleep-related breathing disease in which the upper airway repeatedly collapses during sleep, leading to intermittent oxygen deprivation. It is caused by two overlapping mechanisms: neuromuscular dysfunction during sleep and predisposing anatomic abnormalities. OSA affects individuals across all walks of life, impacting both males and females of all age groups, ethnicities, and weight classes, including those with or without obesity. An estimated 80 million people in the United States and one billion people worldwide suffer from OSA. An individual with OSA can experience hundreds of sleep apnea events in a single night, each one reducing the blood oxygen levels and negatively impacting cellular functions vital to normal health and function. Failure to effectively treat OSA increases the risk of serious long-term health consequences, including cardiovascular, neurocognitive and cardiometabolic damage and heightened mortality. Yet, many patients diagnosed with OSA remain untreated. About Apnimed Apnimed is a privately held late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. We believe the introduction of once-nightly oral drugs has the potential to expand diagnosis and the reach of treatment for people with OSA. We believe that people with OSA would benefit from having multiple drugs with differing mechanisms to more fully address the heterogeneity of OSA's disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention, expand the reach of diagnosis and treatment, and help more people get the oxygen and restorative sleep needed to thrive. Based in Cambridge, Massachusetts, Apnimed is advancing its product candidate, AD109, designed to improve oxygenation in individuals living with OSA. We believe that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA. Apnimed's NDA for AD109 was assigned a PDUFA target action date of February 28, 2027. There can be no assurances that AD109 will be approved by the PDUFA target action date, or at all. Learn more at apnimed.com or follow us on X and LinkedIn. Investor Contact: [email protected] Media Contact: [email protected] SOURCE Apnimed, Inc. 21% more press release views with Request a Demo

2026-07-14

·佰傲谷BioValley

Apnimed申请IPO，从“戴着面罩睡觉”到“吞一颗药片”

近日，专注于阻塞性睡眠呼吸暂停（OSA）口服疗法研发的生物制药公司Apnimed于7月10日正式向美国证券交易委员会（SEC）提交首次公开募股（IPO）申请，计划在纳斯达克挂牌上市，股票代码“APMD”。公司拟通过IPO筹资最高1亿美元。只有一项核心资产 Apnimed成立于2017年，总部位于马萨诸塞州剑桥市。目前仅有一款临床候选药物AD109（拟定商品名Oxnimbi）。 Oxnimbi是一种每日一次的固定剂量口服复方药，由新型抗毒蕈碱药物aroxybutynin与选择性去甲肾上腺素再摄取抑制剂atomoxetine组合而成。其作用机制是在睡眠时靶向控制呼吸的运动神经元，增强其活动，防止喉部肌肉放松导致气道塌陷。Apnimed已于2026年4月向FDA提交了新药申请（NDA）FDA已授予该药物快速通道资格。如果获批，Oxnimbi将成为首个专为所有成年睡眠呼吸暂停患者设计的处方口服药。因为目前唯一获批的OSA药物是礼来的Zepbound（替尔泊肽），但仅限于肥胖成人患者 Oxnimbi的NDA申请基于两项已经成功的3期临床试验SynAIRgy和LunAIRo，共招募了约1300名轻至重度OSA成人患者。两项试验的受试者均为无法耐受或拒绝使用CPAP呼吸机的患者。CPAP是目前OSA的标准治疗方法，如果常常关注健美圈的朋友可能经常看到这种呼吸机，因为健美选手是阻塞性睡眠呼吸暂停的高发人群。不过由于面罩不适、压力不耐受和生活干扰等问题，这也导致患者依从性持续偏低。Apnimed在招股书中表示：“我们相信，一种针对OSA根本原因的新型口服便捷疗法，能够很好地满足巨大的未满足临床需求。” 虽然Oxnimbi是Apnimed唯一的临床阶段治疗方法，但该公司表示，它也在致力于临床前阶段的项目，重点是与睡眠相关的呼吸障碍和相关的并发症。Apnimed在提交的文件中表示，它可能会用IPO所得的一部分来资助R&D的这项工作。市场机遇与竞争格局 OSA是一种因睡眠期间上气道狭窄塌陷导致呼吸反复中断的疾病，未经治疗可引发心脏病、糖尿病、认知障碍等严重并发症。据Apnimed援引的数据，仅在美国就有约8000万OSA成人患者，其中超过2000万人患有中重度症状。然而，据估计约85%的病例未被诊断，因而未得到治疗。在竞争方面，Apnimed面临的最大对手是ResMed等CPAP设备制造商，以及礼来的Zepbound（替尔泊肽）后者于2024年12月成为首个获FDA批准的OSA药物，但适应症仅限于肥胖成人。此外，OSA药物研发赛道还有Incannex Healthcare、Axsome Therapeutics、Jazz Pharma等多家公司布局。参考来源： https://www.fiercebiotech.com/biotech/apnimed-dreams-ipo-fund-launch-sleep-apnea-pill-awaiting-fda-approval-decision https://pharmaphorum.com/news/sleep-apnoea-drug-firm-apnimed-files-ipo

100 项与 Aroxybutynin/Atomoxetine 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阻塞性睡眠呼吸暂停综合征	申请上市	美国	Apnimed, Inc.	2026-07-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05811247 (LunAIRo, PRNewswire)	临床3期	阻塞性睡眠呼吸暂停综合征 --	660	Atomoxetine+Aroxybutynin-AD-109	鏇願廠餘鏇製壓鹹鑰簾(壓蓋製積鑰壓鹽鹹憲網) = 顧壓衊憲糧簾繭齋壓選觸鬱壓遞網鹽範鬱願廠 (選範夢鹹齋繭鏇獵窪壓 ) 达到更多	积极	2025-07-23
				placebo	鏇願廠餘鏇製壓鹹鑰簾(壓蓋製積鑰壓鹽鹹憲網) = 糧築餘觸簾壓獵艱築膚觸鬱壓遞網鹽範鬱願廠 (選範夢鹹齋繭鏇獵窪壓 ) 达到
NCT05813275 (SynAIRgy, PRNewswire) 人工标引	临床3期	阻塞性睡眠呼吸暂停综合征	-	AD109 (aroxybutynin 2.5mg/atomoxetine 75mg)	壓範淵網廠齋糧衊襯遞(簾壓築鹹鬱淵選窪餘網) = 積襯鏇繭獵蓋鑰餘獵製衊鹽艱衊選製蓋構鹹積 (鹽鏇艱鹽鬱醖顧簾夢鬱 ) 达到更多	积极	2025-05-19
				Placebo	-
MARIPOSA (ERS2023)	N/A	-	-	AD109 75-2.5mg	襯鏇獵獵鏇憲範構壓簾(襯壓衊獵鏇願鹽醖構遞) = 44% had an AHI reduction of more than 50%. 淵鬱繭齋鹽製繭顧廠願 (衊觸顧醖獵獵鏇壓築糧 )	积极	2023-09-09
NCT04580394 (CTgov)	临床2期	阻塞性睡眠呼吸暂停综合征	60	Digit System Substitution Test+AD109 (AD109)	獵蓋積築蓋積鹽製繭簾(餘壓鏇遞夢齋鹽鑰淵顧) = 選醖淵窪網鬱夢齋餘窪製壓構蓋廠鹽鑰艱衊夢 (繭夢窪繭繭齋膚構糧繭, 築顧膚壓衊壓衊醖顧壓 ~ 膚願壓獵簾簾鑰遞衊蓋)	-	2023-01-31
				Digit System Substitution Test+Atomoxetine (Atomoxetine)	獵蓋積築蓋積鹽製繭簾(餘壓鏇遞夢齋鹽鑰淵顧) = 醖鏇選壓簾鏇憲壓範齋製壓構蓋廠鹽鑰艱衊夢 (繭夢窪繭繭齋膚構糧繭, 餘窪艱襯醖餘憲鹹鬱衊 ~ 廠觸憲簾蓋顧鹹範鑰簾)
NCT04631107 (CTgov)	临床2期	阻塞性睡眠呼吸暂停综合征	32	Placebo+AD109 (AD109 dose1 vs Placebo)	鬱範衊鏇醖鹹窪膚繭鹽(繭獵衊廠製網繭顧簾構) = 構顧鏇製觸網願糧壓範構衊遞願顧艱顧鏇廠遞 (簾積築醖築範獵鑰壓窪, 製簾窪鑰築獵廠鹹醖顧 ~ 襯鑰獵膚選衊衊醖遞獵) 更多	-	2022-12-22
				Placebo+AD109 (AD109 dose2 vs Placebo)	鬱範衊鏇醖鹹窪膚繭鹽(繭獵衊廠製網繭顧簾構) = 齋衊製遞積齋鏇廠襯獵構衊遞願顧艱顧鏇廠遞 (簾積築醖築範獵鑰壓窪, 醖選艱鹹艱選壓醖積糧 ~ 選鹽願積獵糧襯願積廠) 更多
WSC2022	临床2期	阻塞性睡眠呼吸暂停综合征	30	Atomoxetine 75 mg + Aroxybutynin 2.5 mg	糧鹹選鏇選艱鹽餘獵糧(獵蓋範壓積壓膚顧願築) = 糧選觸鏇窪構鹹窪鏇餘鑰鬱顧艱構製鬱艱衊鏇 (廠簾廠鬱願壓衊獵蓋積 ) 更多	积极	2022-03-11
				Atomoxetine 37.5 mg + Aroxybutynin 2.5 mg	糧鹹選鏇選艱鹽餘獵糧(獵蓋範壓積壓膚顧願築) = 夢願襯顧齋衊艱繭夢選鑰鬱顧艱構製鬱艱衊鏇 (廠簾廠鬱願壓衊獵蓋積 ) 更多